1
|
Zykova MV, Bratishko KA, Buyko EE, Azarkina LA, Ivanov VV, Mihalyov DA, Trofimova ES, Danilets MG, Ligacheva AA, Konstantinov AI, Ufandeev AA, Rabtsevich ES, Drygunova LA, Zima AP, Bashirov SR, Udut EV, Belousov MV. Coal-Derived Humic Substances: Insight into Chemical Structure Parameters and Biomedical Properties. Molecules 2024; 29:1530. [PMID: 38611808 PMCID: PMC11013056 DOI: 10.3390/molecules29071530] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2024] [Revised: 03/23/2024] [Accepted: 03/26/2024] [Indexed: 04/14/2024] Open
Abstract
An investigation was carried out on humic substances (HSs) isolated from the coal of the Kansk-Achinsk basin (Krasnoyarsk Territory, Russia). The coal HSs demonstrate the main parameters of molecular structure inherent to this class of natural compounds. An assessment was performed for the chemical, microbiological, and pharmacological safety parameters, as well as the biological efficacy. The HS sample meets the safety requirements in microbiological purity, toxic metals content (lead, cadmium, mercury, arsenic), and radionuclides. The presence of 11 essential elements was determined. The absence of general, systemic toxicity, cytotoxicity, and allergenic properties was demonstrated. The coal HS sample was classified as a Class V hazard (low danger substances). High antioxidant and antiradical activities and immunotropic and cytoprotective properties were identified. The ability of the HS to inhibit hydroxyl radicals and superoxide anion radicals was revealed. Pronounced actoprotective and nootropic activities were also demonstrated in vivo. Intragastric administration of the HS sample resulted in the improvement of physical parameters in mice as assessed by the "swim exhaustion" test. Furthermore, intragastric administration in mice with cholinergic dysfunction led to a higher ability of animals with scopolamine-induced amnesia to form conditioned reflexes. These findings suggest that the studied HS sample is a safe and effective natural substance, making it suitable for use as a dietary bioactive supplement.
Collapse
Affiliation(s)
- Maria V. Zykova
- Pharmaceutical Faculty, Siberian State Medical University, 634050 Tomsk, Russia; (K.A.B.); (E.E.B.); (L.A.A.); (V.V.I.); (D.A.M.); (E.S.T.); (A.A.U.); (E.S.R.); (L.A.D.); (A.P.Z.); (S.R.B.); (E.V.U.); (M.V.B.)
| | - Kristina A. Bratishko
- Pharmaceutical Faculty, Siberian State Medical University, 634050 Tomsk, Russia; (K.A.B.); (E.E.B.); (L.A.A.); (V.V.I.); (D.A.M.); (E.S.T.); (A.A.U.); (E.S.R.); (L.A.D.); (A.P.Z.); (S.R.B.); (E.V.U.); (M.V.B.)
| | - Evgeny E. Buyko
- Pharmaceutical Faculty, Siberian State Medical University, 634050 Tomsk, Russia; (K.A.B.); (E.E.B.); (L.A.A.); (V.V.I.); (D.A.M.); (E.S.T.); (A.A.U.); (E.S.R.); (L.A.D.); (A.P.Z.); (S.R.B.); (E.V.U.); (M.V.B.)
| | - Lyudmila A. Azarkina
- Pharmaceutical Faculty, Siberian State Medical University, 634050 Tomsk, Russia; (K.A.B.); (E.E.B.); (L.A.A.); (V.V.I.); (D.A.M.); (E.S.T.); (A.A.U.); (E.S.R.); (L.A.D.); (A.P.Z.); (S.R.B.); (E.V.U.); (M.V.B.)
| | - Vladimir V. Ivanov
- Pharmaceutical Faculty, Siberian State Medical University, 634050 Tomsk, Russia; (K.A.B.); (E.E.B.); (L.A.A.); (V.V.I.); (D.A.M.); (E.S.T.); (A.A.U.); (E.S.R.); (L.A.D.); (A.P.Z.); (S.R.B.); (E.V.U.); (M.V.B.)
| | - Dmitrii A. Mihalyov
- Pharmaceutical Faculty, Siberian State Medical University, 634050 Tomsk, Russia; (K.A.B.); (E.E.B.); (L.A.A.); (V.V.I.); (D.A.M.); (E.S.T.); (A.A.U.); (E.S.R.); (L.A.D.); (A.P.Z.); (S.R.B.); (E.V.U.); (M.V.B.)
| | - Evgeniya S. Trofimova
- Pharmaceutical Faculty, Siberian State Medical University, 634050 Tomsk, Russia; (K.A.B.); (E.E.B.); (L.A.A.); (V.V.I.); (D.A.M.); (E.S.T.); (A.A.U.); (E.S.R.); (L.A.D.); (A.P.Z.); (S.R.B.); (E.V.U.); (M.V.B.)
- Goldberg Research Institute of Pharmacology and Regenerative Medicine, 634050 Tomsk, Russia; (M.G.D.); (A.A.L.)
| | - Marina G. Danilets
- Goldberg Research Institute of Pharmacology and Regenerative Medicine, 634050 Tomsk, Russia; (M.G.D.); (A.A.L.)
| | - Anastasia A. Ligacheva
- Goldberg Research Institute of Pharmacology and Regenerative Medicine, 634050 Tomsk, Russia; (M.G.D.); (A.A.L.)
| | - Andrey I. Konstantinov
- Department of Chemistry, Lomonosov Moscow State University, Leninskiye Gory 1-3, 119991 Moscow, Russia;
| | - Alexander A. Ufandeev
- Pharmaceutical Faculty, Siberian State Medical University, 634050 Tomsk, Russia; (K.A.B.); (E.E.B.); (L.A.A.); (V.V.I.); (D.A.M.); (E.S.T.); (A.A.U.); (E.S.R.); (L.A.D.); (A.P.Z.); (S.R.B.); (E.V.U.); (M.V.B.)
| | - Evgenia S. Rabtsevich
- Pharmaceutical Faculty, Siberian State Medical University, 634050 Tomsk, Russia; (K.A.B.); (E.E.B.); (L.A.A.); (V.V.I.); (D.A.M.); (E.S.T.); (A.A.U.); (E.S.R.); (L.A.D.); (A.P.Z.); (S.R.B.); (E.V.U.); (M.V.B.)
- Tomsk State University, 634050 Tomsk, Russia
| | - Larisa A. Drygunova
- Pharmaceutical Faculty, Siberian State Medical University, 634050 Tomsk, Russia; (K.A.B.); (E.E.B.); (L.A.A.); (V.V.I.); (D.A.M.); (E.S.T.); (A.A.U.); (E.S.R.); (L.A.D.); (A.P.Z.); (S.R.B.); (E.V.U.); (M.V.B.)
| | - Anastasia P. Zima
- Pharmaceutical Faculty, Siberian State Medical University, 634050 Tomsk, Russia; (K.A.B.); (E.E.B.); (L.A.A.); (V.V.I.); (D.A.M.); (E.S.T.); (A.A.U.); (E.S.R.); (L.A.D.); (A.P.Z.); (S.R.B.); (E.V.U.); (M.V.B.)
| | - Sergey R. Bashirov
- Pharmaceutical Faculty, Siberian State Medical University, 634050 Tomsk, Russia; (K.A.B.); (E.E.B.); (L.A.A.); (V.V.I.); (D.A.M.); (E.S.T.); (A.A.U.); (E.S.R.); (L.A.D.); (A.P.Z.); (S.R.B.); (E.V.U.); (M.V.B.)
| | - Elena V. Udut
- Pharmaceutical Faculty, Siberian State Medical University, 634050 Tomsk, Russia; (K.A.B.); (E.E.B.); (L.A.A.); (V.V.I.); (D.A.M.); (E.S.T.); (A.A.U.); (E.S.R.); (L.A.D.); (A.P.Z.); (S.R.B.); (E.V.U.); (M.V.B.)
| | - Mikhail V. Belousov
- Pharmaceutical Faculty, Siberian State Medical University, 634050 Tomsk, Russia; (K.A.B.); (E.E.B.); (L.A.A.); (V.V.I.); (D.A.M.); (E.S.T.); (A.A.U.); (E.S.R.); (L.A.D.); (A.P.Z.); (S.R.B.); (E.V.U.); (M.V.B.)
| |
Collapse
|
2
|
Drug screening for Pelizaeus-Merzbacher disease by quantifying the total levels and membrane localization of PLP1. Mol Genet Metab Rep 2019; 20:100474. [PMID: 31110947 PMCID: PMC6510973 DOI: 10.1016/j.ymgmr.2019.100474] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2019] [Accepted: 04/28/2019] [Indexed: 01/01/2023] Open
Abstract
Background Pelizaeus-Merzbacher disease (PMD) is caused by point mutations or copy number changes in the proteolipid protein 1 gene (PLP1). PLP1 is exclusively localized in the myelin sheath of oligodendrocytes. Amino acid-substituted PLP1 protein is unable to fold properly and is subsequently degraded and/or restrictedly translated, resulting in a decrease in the PLP1 protein level and a failure to localize to the membrane. Furthermore, misfolded proteins increase the burden on the intracellular quality control system and trafficking, finally resulting in cell apoptosis. The objective of this study was to identify therapeutic chemicals for PMD by quantifying the total levels and membrane localization of PLP1. Method We established a cell line stably expressing PLP1A243V fused with green fluorescent protein in oligodendrocyte-derived MO3.13 cells. We screened a chemical library composed of drugs approved for central nervous system disorders that increased both the total intensity of PLP1A243V in the whole cell and the cell membrane localization. We analyzed the change in the endoplasmic reticulum (ER) stress and the gene expression of candidate chemicals using a micro-array analysis. Finally, we tested the in vivo effectiveness using myelin synthesis deficient (msd) mice with PlpA243V. Results and conclusion Piracetam significantly increased the PLP1A243V intensity and membrane localization and decreased the ER stress. It was also shown to reverse the gene expression changes induced by PLP1A243V in a micro-array analysis. However, in vivo treatment of piracetam did not improve the survival of msd mice (Plp1A243V).
Collapse
Key Words
- CNS, Central nervous systems
- Drug screening
- EGFP, Enhanced green fluorescent protein
- ER, Endoplasmic reticulum
- ER-associated degradation
- Gene expression
- IPA, Ingenuity pathways analysis
- IRE1 α, Inositol requiring enzyme 1 α
- Membrane protein
- Oligodendrocyte
- PLP1
- PLP1, Proteolipid protein 1
- PMD, Pelizaeus-Merzbacher disease
- UPR, Unfolded protein response
- XBP1, X-box binding protein 1
- msd, Myelin synthesis deficient
Collapse
|